Event-Driven Stocks

AMGEN INC

AMGNNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$36.75B$33.42B$28.19B$26.32B$25.98B$25.42B
Operating income$9.08B$7.26B$7.90B$9.57B$7.64B$9.14B
Net income$7.71B$4.09B$6.72B$6.55B$5.89B$7.26B
Total assets$90.59B$91.84B$97.15B$65.12B$61.16B$62.95B
Total liabilities——————
Equity$8.66B$5.88B$6.23B$3.66B$6.70B$9.41B
EPS (diluted)$14.23$7.56$12.49$12.11$10.28$12.31
Shares out.537.2M535.9M534.0M557.0M577.6M589.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
24.7%
Net margin
21.0%
Return on equity
89.1%
Return on assets
8.5%
Return on capital (ROCE)
13.9%
Liabilities / assets
—
Debt / equity
—
Book value / share
$16.12
Revenue growth (YoY)
10.0%
Net income growth (YoY)
88.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−2.5%clean
Piotroski F-Score
6/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
87
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 5 good
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • BLINCYTODec 3, 2014
  • PROLIAJun 1, 2010
  • NPLATEAug 22, 2008
  • VECTIBIXSep 27, 2006
  • SENSIPARMar 8, 2004
  • NEULASTAJan 31, 2002
  • ARANESPSep 17, 2001
  • NEUPOGENFeb 20, 1991

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202612.3M4.3-5.2%
Apr 30, 202613.0M5.3+1.7%
Apr 15, 202612.7M5.3-8.8%
Mar 31, 202614.0M4.7-2.4%
Mar 13, 202614.3M6.1-5.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (4)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.